Thursday, March 1, 2018

12:00 p.m. Registration and Refreshments
12:45 Welcome Announcements

INTERACTIVE CASE PRESENTATIONS
Moderator: Robert R. McWilliams, M.D.

1:00 Advanced Non-Metastatic Pancreas Cancer: How to Maximize Chances of Successful Resection?
Case Presenter: Mark J. Truty, M.D., M.S.
Panel: Michael L. Kendrick, M.D., Robert R. McWilliams, M.D., Ramesh K. Ramanathan, M.D., Terence T. Sio, M.D., M.S., Mark J. Truty, M.D., M.S.

1:55 Early Stage Rectal Cancer
Discussion 1: Do Shorter Total Neo-Adjuvant Courses Make More Sense?
Case Presenter: Nitin Mishra, M.D.
Panel: David A. Etzioni, M.D., Chris L. Hallemeier, M.D., Joleen M. Hubbard, M.D., Pashtoon M. Kasi, M.D., Amit Merchea, M.D., Nitin Mishra, M.D.

Discussion 2: Is There a Role for Non-Operative Management?
Case Presenter: Chris L. Hallemeier, M.D.
Panel: David A. Etzioni, M.D., Chris L. Hallemeier, M.D., Joleen M. Hubbard, M.D., Pashtoon M. Kasi, M.D., Amit Merchea, M.D., Nitin Mishra, M.D.

2:50 Break

3:10 Early Stage Gastro-Esophageal Cancer: How to Optimize Neoadjuvant Therapy to Maximize Benefit?
Case Presenter: Harry H. Yoon, M.D.
Panel: Daniel H. Ahn, D.O., Jonathan B. Ashman, M.D., Ph.D., Dennis Wigle, M.D., Ph.D., Harry H. Yoon, M.D.

4:05 Locally Advanced Hepatocellular Carcinoma: Local vs. Systemic Therapy
Case Presenter: Mitesh J. Borad, M.D.
Panel: Mitesh J. Borad, M.D., Amit Mahipal, M.B.B.S., Kabir Mody, M.D., Rahmi Oklu, M.D., Ph.D., Beau Toskich, M.D.

5:00 Closing Remarks
5:05 Adjourn
Friday, March 2, 2018

7:00 a.m. Continental Breakfast

7:50 Announcements

SESSION I: EMERGING TREATMENT STRATEGIES IN GASTRO-ESOPHAGEAL CANCER
Moderator: Jonathan B. Ashman, M.D., Ph.D.

8:00 Integrating PET Scans in the Decision-Making for GE Cancer Treatment
    Michael C. Roarke, M.D.

8:20 Immunotherapeutic Strategies in GE Cancer: Who is a Candidate?
    Harry H. Yoon, M.D.

8:40 Anti-Angiogenic Agents in GE Cancer: Where Do They Fit in the Therapeutic Landscape?
    Daniel Ahn, D.O.

9:00 Minimally Invasive Surgical Interventions in Early-Stage GE Cancer
    Dennis Wigle, M.D., Ph.D.

9:20 Break

SESSION II: EMERGING STRATEGIES TO OPTIMIZE OUTCOME IN METASTATIC COLORECTAL CANCER (mCRC)
Moderator: Axel Grothey, M.D.

9:40 From Anatomical location to CMS classification: Implications on Treatment Approach
    Heinz-Josef Lenz, M.D., FACP

10:00 The Emerging Role of “Liquid Biopsies” in the Treatment Landscape of mCRC
    John Strickler, M.D.

10:20 BRAF and RAS Mutations in mCRC : How I Treat?
    Scott Kopetz, M.D., Ph.D., FACP

10:40 Immunotherapeutic Strategies in CRC: Beyond MSI-high and Advanced Settings?
    Frank A. Sinicrope, M.D.

11:00 Predictors of Outcome with Regorafenib and TAS102
    Pashtoon M. Kasi, M.D.

11:40 Lunch
SESSION III: OPTIMIZING OUTCOME IN EARLY STAGE AND OLIGO-METASTATIC COLORECTAL CANCER
Moderator: Nitin Mishra, M.D.

12:30 p.m. Radioembolization in Liver-only or Liver-dominant mCRC: Is there a Fit?
Steven R. Alberts, M.D.

12:50 Liver Resection in mCRC: Who is an Optimal Candidate?
Chee-Chee H. Stucky, M.D.

1:10 Survivorship in the Long-term Care of Patients with CRC
David A. Etzioni, M.D.

1:30 Optimal Duration in the Adjuvant Treatment of CRC: Do We Have an IDEA?
Axel Grothey, M.D.

1:50 Debate: Role of HIPEC in the Management of CRC with Peritoneal only Disease
HIPEC Rules! – Nabil Wasif, M.D.
Time to Move Beyond HIPEC! – Amit Merchea, M.D.
Panel Discussion – Nabil Wasif, M.D. and Amit Merchea, M.D.

2:30 Break

SESSION IV: INTERPRETATION OF CLINICAL TRIALS AND LARGE DATABASES IN GI CANCERS
Moderator: Qian Shi, Ph.D.

2:50 Clinical Trial Conduct and Monitoring
Fang-Shu Ou, Ph.D.

3:10 Working with Large Databases (ACCENT, ARCAD, and IDEA):
The Past as Prologue
Qian Shi, Ph.D.

3:30 Closing Remarks

3:35 Adjourn
Saturday, March 3, 2018

7:00 a.m. Continental Breakfast
7:50 Announcements

SESSION V: EMERGING TREATMENT STRATEGIES IN PANCREAS CANCER
Moderator: Ramesh K. Ramanathan, M.D.

8:00 Optimizing Sequencing in the Treatment of Metastatic Pancreas Cancer
Wen Wee Ma, M.B.B.S.

8:20 Emerging Strategies in the Treatment of Metastatic Pancreas Cancer
Ignacio Garrido-Laguna, M.D., Ph.D.

8:40 Total Neoadjuvant Treatment for Resectable Pancreas Cancer: Is it Time?
Mark J. Truty, M.D., M.S.

9:00 Minimally Invasive Surgical Interventions in Pancreas Cancer
Michael L. Kendrick, M.D.

9:20 Break

SESSION VI: EMERGING STRATEGIES TO OPTIMIZE OUTCOME IN HEPATOBILIARY CANCERS
Moderator: Daniel Ahn, D.O.

9:40 Tyrosine Kinase Inhibitors Galore: What is the Optimal Sequence?
Mitesh J. Borad, M.D.

10:00 Immunotherapeutic Strategies in HCC: A Shifting Landscape
Anthony B. El-Khoueiry, M.D.

10:20 The Expanding Role of Proton Therapy in Localized Hepatobiliary Cancers
Jonathan B. Ashman, M.D., Ph.D.

10:40 When to Refer Your Patient with Hepatobiliary Cancer for Consideration of Transplant?
Adyr A. Moss, M.D.

11:00 Genetic Diversity in Biliary Cancer
Milind Javle, M.D.

11:20 Debate: Role of Adjuvant Therapy in Biliary Cancer
Chemotherapy is the Standard – Bassel F. El-Rayes, M.D.
Observation is the Standard – Kabir Mody, M.D.
Panel Discussion – Bassel F. El-Rayes, M.D. and Kabir Mody, M.D.

12:00 p.m. Lunch
SESSION VII: NEUROENDOCRINE CANCER
Moderator: Amit Mahipal, M.D.

12:50 Surgical (including Liver Transplant) Options in Metastatic NET to the Liver: Who is a Candidate? Amit K. Mathur, M.D.

1:10 Systemic Therapies in NET Thorvardur R. Halfdanarson, M.D.

1:30 Emerging Strategies in the Treatment Landscape of NET Jonathan R. Strosberg, M.D.

SPECIAL LECTURES
Moderator: Tanios S. Bekaii-Saab, M.D.

1:50 Her2 as a Target in GI Malignancies John H. Strickler, M.D.

2:05 Biosimilars Are Not Biosames: So What? Tanios S. Bekaii-Saab, M.D.

2:30 Closing Remarks

2:35 Adjourn